Last updated Jun 7, 2026
Eli Lilly
Evidence Sources
4
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
0
Clinical Programs
1
Confidence Coverage
77%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Obesity
- Triple Agonist
Highest priority development: Lilly's Retatrutide Trial Results Disrupt Obesity Treatment Landscape
Competitive pressure: Low
Portfolio impact: Moderate
Evidence coverage: 77%
Active Signals
1
Investigate Priority
0
Opportunity Score
24
Buyer Quality
10 · Enterprise
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 7, 2026Score 24Lilly's Retatrutide Shows Significant Weight Loss and Pain Reduction in TRIUMPH-1 Trial
Obesity · Triple Agonist
Related Assets
Portfolio asset pages with evidence-based assessments.
- Lilly's Retatrutide Trial Results Disrupt Obesity Treatment LandscapeModerate Confidence · 78%
Portfolio asset at Approved stage
Sources (3)AutoResearchCompetitivaRegunera
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
No regulatory precedents are linked yet.
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
- Lilly's Retatrutide Trial Results Disrupt Obesity Treatment LandscapeModerate Confidence · 76%
Clinical program tracked via asset intelligence
Sources (2)AutoResearchClinicalTrials.gov
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Eli Lilly right now?
- Which regulatory precedents should Eli Lilly monitor in Obesity and Triple Agonist?
- How does Lilly's Retatrutide Trial Results Disrupt Obesity Treatment Landscape compare to the nearest competitive programs?
- What signals require immediate investigation for Eli Lilly?
- Summarize the strategic implications of recent developments for Eli Lilly.
- Where is the greatest uncertainty in Eli Lilly's competitive positioning?